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Significance of this study
What is already known about this subject?
 ► The original version of the German Diabetes Risk 
Score (GDRS) including only non-invasively mea-
sured risk factors is an accurate and valid tool for 
prediction of diabetes risk.
 ► Previous research suggests that biomarkers like 
hemoglobin A1c (HbA1c) improve prediction beyond 
non-invasive risk factors.
What are the new findings?
 ► Including HbA1c in the GDRS (clinical GDRS) im-
proved the accuracy of prediction for incident 
diabetes—particularly among future diabetes cas-
es—and application of this clinical GDRS in a na-
tionwide cohort confirmed external validity with 
excellent discrimination as well as good calibration.
How might these results change the focus of 
research or clinical practice?
 ► The clinical GDRS represents a validated tool for 
predicting diabetes in clinical practice and may 
be applied by physicians to enable the evaluation 
of the patient’s risk profile from a more detailed 
perspective.
AbStrAct
Objective  The German Diabetes Risk Score (GDRS) is 
a diabetes prediction model which only includes non-
invasively measured risk factors. The aim of this study was 
to extend the original GDRS by hemoglobin A1c (HbA1c) 
and validate this clinical GDRS in the nationwide German 
National Health Interview and Examination Survey 1998 
(GNHIES98) cohort.
Research design and methods  Extension of the GDRS 
was based on the European Prospective Investigation into 
Cancer and Nutrition (EPIC)-Potsdam study with baseline 
assessment conducted between 1994 and 1998 (N=27 
548, main age range 35–65 years). Cox regression was 
applied with the original GDRS and HbA1c as independent 
variables. The extended model was evaluated by 
discrimination (C-index (95% CI)), calibration (calibration 
plots and expected to observed (E:O) ratios (95% CI)), and 
reclassification (net reclassification improvement, NRI 
(95% CI)). For validation, data from the GNHIES98 cohort 
with baseline assessment conducted between 1997 
and 1999 were used (N=3717, age range 18–79 years). 
Missing data were handled with multiple imputation.
Results  After 5 years of follow-up 593 incident cases 
of type 2 diabetes occurred in EPIC-Potsdam and 86 in 
the GNHIES98 cohort. In EPIC-Potsdam, the C-index for 
the clinical GDRS was 0.87 (0.81 to 0.92) and the overall 
NRI was 0.26 (0.21 to 0.30), with a stronger improvement 
among cases compared with non-cases (NRIcases: 0.24 
(0.19 to 0.28); NRInon-cases: 0.02 (0.01 to 0.02)). Almost 
perfect calibration was observed with a slight tendency 
toward overestimation, which was also reflected by an 
E:O ratio of 1.07 (0.99 to 1.16). In the GNHIES98 cohort, 
discrimination was excellent with a C-index of 0.91 
(0.88 to 0.94). After recalibration, the calibration plot 
showed underestimation of diabetes risk in the highest 
risk group, while the E:O ratio indicated overall perfect 
calibration (1.02 (0.83 to 1.26)).
Conclusions  The clinical GDRS provides the opportunity 
to apply the original GDRS as a first step in risk 
assessment, which can then be extended in clinical 
practice with HbA1c whenever it was measured.
InTROduCTIOn
The clinical value of risk scores in the context 
of detection of high-risk individuals and 
prevention has been confirmed by imple-
mentation of the Framingham Risk Score1–3 
and by recommendations within the Euro-
pean prevention guidelines for cardiovascular 
diseases.4 While prediction models including 
only non-invasively measured risk factors 
are advantageous for application among the 
general population and thus enabling layper-
sons to estimate their individual diabetes risk, 
prediction models including clinical markers 
are targeted toward the clinical setting where 
information about blood parameters is 
readily available. For diabetes, various predic-
tion models were developed within the past 
decades, including models based on solely 
non-invasively measured risk factors or on 
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additional clinical markers.5 6 However, only a limited 
number of these models were externally validated or 
provided an instrument for use in clinical practice.5 
Thus, only a few diabetes risk scores have the potential 
for application in the clinical context. One advantage 
of such an application was shown in a recent study indi-
cating that preceding risk calculation based on risk scores 
may enhance the uptake of screening activities, especially 
those including blood tests.7 Such a stepwise approach 
with identification of high-risk individuals and following 
blood test might also be valuable in a longer perspective 
in terms of cost-effectiveness of lifestyle interventions in 
diabetes prevention strategies (Kristin Mühlenbruch, 
Submitted, 2018) . For hemoglobin A1c (HbA1c) it was 
shown that targeting prevention interventions to high-
risk individuals based on HbA1c alone was cost-effective.8 
Additionally, results from a previous study indicate that 
HbA1c, although still in the normal range, is related to 
an increased diabetes risk, suggesting that it might also 
be informative for diabetes risk prediction.9 Therefore, 
inclusion of HbA1c as a clinical marker might entail the 
potential to improve prediction, and to increase success 
of screening strategies in terms of acceptance, participa-
tion and cost-effectiveness for diabetes prevention.”
The German Diabetes Risk Score (GDRS), which orig-
inally only includes non-invasively measured risk factors, 
is an accurate and valid tool for diabetes prediction.10–12 
Previous reports of model extensions with glucose markers 
showed relevant improvement in prediction accuracy.13 
However, a clinical version was so far not available since 
HbA1c was only measured in a case-cohort study design 
with over-representation of diabetes cases. Absolute risk 
estimation was not possible from this design; however, a 
recent study showed that multiple imputation (MI) was a 
valid approach for absolute risk estimation from case-co-
hort studies.14 Therefore, the aim of this study was to 
extend the GDRS with HbA1c using MI in a first step, and 
in a second step to validate the derived scoring algorithm 
in a nationwide German cohort. The approach applied 
in this study offers the opportunity to maintain a version 
of the GDRS including only non-invasively measured risk 
factors which is targeted at the general population, and 
at the same time to provide a version including HbA1c 





The  European Prospective Investigation into Cancer and 
Nutrition (EPIC)-Potsdam study is a prospective cohort 
study comprising 27 548 participants from the general 
adult population mainly aged between 35 and 65 years. 
Participants were recruited from 1994 to 1998 in Potsdam 
and surrounding municipalities; follow-up assessment 
was performed every 2–3 years and was mainly question-
naire-based.15 16 For follow-up rounds 1, 2, 3, and 4 (by 
August 2005), follow-up procedures successfully achieved 
response rates of 96%, 95%, 91% and 90%, respectively.17 
The baseline assessment included physical examinations, 
a personal interview, a lifestyle questionnaire and a Food 
Frequency Questionnaire (FFQ).
Follow-up questionnaires were used for the identifi-
cation of incident diabetes.17 Systematic information 
sources for incident cases were self-reports of a type 2 
diabetes (T2D) diagnosis, T2D-relevant medication, 
and dietary treatment due to T2D during follow-up. 
Furthermore, we obtained additional information from 
death certificates or from random sources, such as tumor 
centers, physicians, or clinics that provided assessments 
from other diagnoses. Although self-reports of T2D were 
generally reliable, by including other sources of informa-
tion, we even improved the completeness of case ascer-
tainment. Once a participant was identified as a potential 
case, disease status was further verified by sending a stan-
dard inquiry form to the treating physician. Only physi-
cian-verified cases with a diagnosis of T2D (International 
Classification of Diseases, 10th revision code: E11) and 
a diagnosis date after the baseline examination were 
considered confirmed incident cases of T2D.
Erythrocyte levels of A1c were measured in a case-co-
hort nested within the EPIC-Potsdam cohort. For 
the construction of this case-cohort study, a random 
subcohort (n=2500) based on 26 437 participants who 
provided blood was drawn and all incident diabetes cases 
with available blood samples (n=820) were included. 
Measurements were performed at the university clinic 
in Tübingen with the automatic ADVIA 1650 analyzer 
(Siemens Medical Solutions, Erlangen, Germany). 
Measured HbA1c values were generally too high for 
a healthy population with a median of 6.38% (mean: 
6.47%, SD: 0.68%) in the random subcohort, and there-
fore representative German survey data were used to 
correct these values. Based on 6266 participants without 
known diabetes of the  German National Health Inter-
view and Examination Survey 1998  (GNHIES98) with a 
mean HbA1c of 5.47% (SD: 0.61%), a prediction model 
was derived including age (years), sex (female) and waist 
circumference (cm) as the predictors:
 
HbA1c_pred = 4.02055458 + 0.01153100 × age + 0.01734449×
Sex + 0.01007337 × waist  
Comparing the measured HbA1c values with those 
expected in the case-cohort study nested within the EPIC-
Potsdam study by applying the prediction model resulted 
in a mean difference of 0.98% points; this means that the 
measured values were about 1% point higher as expected. 
Consequently, the following correction was applied:
 HbA1c_corrected = HbA1c_measured − 0.98 
Although HbA1c was only measured in the case-cohort 
study, the analysis was performed in the full cohort, and 
we excluded prevalent diabetes cases (n=1554), non-ver-
ified diabetes cases (n=13) and participants with missing 
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follow-up and/or age at follow-up (n=589); 25 392 partic-
ipants remained for analysis. Within a mean follow-up 
time of 7 years, 857 incident diabetes cases were observed, 
and 593 incident cases after 5 years of follow-up.
GNHIES98 cohort
The study population comprised individuals who partic-
ipated in both the ‘German National Health Interview 
and Examination Survey 1998’ (GNHIES98, 1997–1999) 
and the following ‘German Health Interview and Exam-
ination Survey for Adults’ (DEGS1, 2008–2011). The 
GNHIES98 included a representative sample of the 
general population in Germany aged 18–79 years. A 
two-stage stratified sampling strategy was applied based 
on information from local population registries.18 Out of 
7124 participants of the GNHIES98, a total of 3959 repar-
ticipated in DEGS1, corresponding to a follow-up rate of 
62%.19 At baseline (GNHIES98), a standardized self-ad-
ministered questionnaire including an FFQ was applied, 
and a standardized physician-administered interview as 
well as physical examinations were conducted.
Incident cases of diagnosed T2D at follow-up (DEGS1) 
were defined as (1) self-reported physician-diagnosed 
diabetes assessed in a standardized physician-admin-
istered interview or (2) intake of antidiabetic medica-
tion within the 7 days before the interview documented 
through an automated assessment of medication. Both 
had to be reported for the first time at follow-up. Inci-
dent cases of type 1 diabetes were excluded by taking 
information on the age at diagnosis and on insulin treat-
ment after diagnosis and at the time of the interview 
into account. Incident cases of gestational diabetes were 
excluded by considering information on whether the 
diagnosis had occurred during pregnancy and whether 
diabetes during the last 12 months or current taking of 
antidiabetic medication was reported.20
In GNHIES98, HbA1c was measured in fresh whole 
blood specimens in the Robert Koch Institute Central 
Epidemiological Laboratory. For blood analyses, a Diamat 
high-performance liquid chromatography analyzer (Bio-
Rad Laboratories, Munich, Germany) was used and 
reagents of Recipe (Recipe Chemicals and Instruments, 
Munich, Germany) were applied.21
Exclusion criteria included prevalent diabetes at base-
line (n=132), missing information on diabetes diagnosis 
at baseline (n=11) or follow-up (n=37), incident gesta-
tional diabetes or type 1 diabetes (n=25), and missing or 
implausible age of diabetes diagnosis at follow-up (n=37), 
yielding a final ‘GNHIES98 – longitudinal sample’ of 
3717 participants. Within a mean follow-up time of 12 
years, 230 incident diabetes cases were observed, and 86 
incident cases after 5 years of follow-up.
Calculation of the GdRs and assessment of GdRs 
components in the GnHIes98 cohort
The GDRS is based on modifiable and non-modifiable 
non-invasively measurable risk factors as described previ-
ously.10 11 22 Calculation of the GDRS points is based on 
individual risk factor values and corresponding coeffi-
cients from Cox regression as presented in the following 
equation:
 
GDRS points = 5.1 × Age (years)
−2.7 × Height (cm)
+7.6 × Waist circumference (cm)
+47 × Prevalent hypertension
−2 × Physical activity (h/week)
+15 × Former smoking (< 20 units/day)
+45 × Former smoking (≥ 20 units/day)
+23 × Current smoking (< 20 units/day)
+77 × Current smoking (≥ 20 units/day)
−7 × Wholegrain intake (50g/day)
−5 × Coffee intake (150g/day)
+55 × Red meat consumption (150g/day)
+56 × One parent with diabetes
+106 × Both parents with diabetes
+48 × A sibling with diabetes  
Individual score points, mean score points and base-
line survival were used for calculation of individual 5-year 
risks using the published equation14:
 P(Diabetes) = 1 − 0.99061
exp
(




The assessment of the GDRS components in the 
GNHIES98 cohort has previously been described and 
was mostly comparable with the assessment in EPIC-
Potsdam.12 Since sibling history of diabetes was not 
assessed in the GNHIES98 cohort, it was imputed by 
the prevalence of a sibling history of diabetes (5.1%) 
observed in EPIC-Potsdam in accordance with previous 
validation studies.10 12 Physical activity was assessed as 
regular sport activity by the following five categories: ‘no 
sport’, ‘<1 hour/week’, ‘1–2 hours/week’, ‘2–4 hours/
week’, and ‘>4 hours/week’. To create a quasi-continuous 
variable, the mean time of each category was assigned to 
the respective category, that is, 0, 0.5, 1.5, 3.0 and 4.5 
hours/week. Furthermore, only frequencies of dietary 
intake were assessed. To estimate the amount of intake 
for each dietary component of the GDRS, information 
from a subset of 4030 out of the 7124 GNHIES98 partic-
ipants who took part in the Nutrition Survey module 
comprising a detailed diet history interview was used as 
previously described.12
statistical analysis
In EPIC-Potsdam, missing values were handled with MI 
with a number of m=10 imputations. This applies to the 
outcome (incident diabetes), components of the GDRS, 
auxiliary variables which were used for the imputation 
model, and HbA1c (online supplementary table S1). 
HbA1c was not measured for participants outside the 
previously described case-cohort and was assumed to be 
missing at random due to the design of the case-cohort 
study. The validity of this approach was confirmed in a 
recent methodological investigation based on data from 
 on 23 A











are: first published as 10.1136/bm




4 BMJ Open Diab Res Care 2018;6:e000524. doi:10.1136/bmjdrc-2018-000524
Epidemiology/Health Services Research
the EPIC-Potsdam study.14 For imputation, variables were 
sorted by the amount of missing values and imputed with 
application of chained equations with imputation models 
specified for each variable separately.
Cox regression was performed to derive the clin-
ical GDRS model, with the score points of the original 
non-invasive GDRS and HbA1c as the independent vari-
ables in the model. Thus, score points for the clinical 
GDRS were derived from the beta-coefficients for both 
from this model. Results from the single imputation data 
sets were combined by application of Rubin’s rules.23 
Baseline survival estimates were combined as proposed 
by Marshall et al.24 Individual risks were then calculated 
using combined MI estimates of the mean score points of 
the clinical GDRS, individual score points of the clinical 
GDRS and baseline survival from Cox regression. Model 
performance was evaluated by discrimination, reclassifi-
cation and calibration; results from the single MI data sets 
were averaged to get overall estimates of the C-index25 of 
the net reclassification improvement (NRI) and for cali-
bration. Calibration was evaluated as calibration-in-the-
large by comparing the mean predicted risk with observed 
incidence, graphically with a calibration plot, and with 
expected to observed (E:O) ratio with 95% CIs, assuming 
a Poisson variance.26 The NRI was computed using four 
predefined risk categories which are currently used for 
communication of GDRS test results (low risk: <2%; still 
low risk: 2% to <5%; increased risk: 5% to <10%; high or 
very high risk ≥10% 5-year risk). The single NRI compo-
nents as well as the overall estimate were presented with 
95% CI as proposed by Mühlenbruch et al.27 For calibra-
tion, the same four risk groups were analyzed.
For validation in the GNHIES98 cohort, missing 
values in the GDRS components and in HbA1c were also 
handled with MI (m=10). Besides the outcome (inci-
dent diabetes), variables for calculation of the GDRS, 
auxiliary variables and HbA1c, the imputation model 
further included the cluster variable and the weighting 
factor (online supplementary table S2).28 29 The cluster 
variable accounts for the complex survey design, 
whereas the weighting factor accounts for differences 
between the survey sample and the general population 
and for the incomplete follow-up.30 MI of the missing 
values and combination of the results from the single 
imputed data sets was conducted as described for EPIC-
Potsdam. However, for combining the results from the 
single imputation data sets in the GNHIES98 cohort, 
SAS (V.9.4) survey procedures again considering the 
cluster variable and the weighting factor28 were applied. 
Based on logistic regression, discrimination was assessed 
through the area under the receiver operating char-
acteristic curve, which in this case is equivalent to the 
C-index. The 95% CI of the C-index was estimated 
performing B=1000 bootstrap draws followed by m=1 
imputation as suggested by Wahl et al.31 For the boot-
strap procedure the individual sample points of the 
GNHIES98 were resampled,32 and the 2.5% and the 
97.5% percentiles of the bootstrapped distribution were 
then used as confidence limits. Calibration was assessed 
as described for EPIC-Potsdam. Since the outcome’s 
incidence in the study population has a strong influence 
on model calibration, we recalibrated the clinical GDRS 
to the incidence in the GNHIES98 cohort as described 
by Kengne et al.33 34
 Precalibrated = 1 − exp(−exp
(+log(−log(1−PClinicalGDRS))) )
 
With PClinicalGDRS estimated from the derived equation 
for the clinical GDRS for each individual and with α as a 
correction factor calculated from the following equation:
 α = log(−log (1 − 0.0226)) − log(−log (1 − 0.0347368)) 
Where 0.0226 is equivalent to the 5-year diabetes inci-
dence in the GNHIES98 cohort as estimated from Kaplan-
Meier methods and 0.0347368 is equivalent to the mean 
estimated 5-year diabetes risk from the clinical GDRS.
In both EPIC-Potsdam and GNHIES98 cohort, all 
statistical analyses were performed with SAS (V.9.4). 
The imputation was performed with the SAS procedures 
PROC MI under usage of the fully conditional specifica-
tion methods (Fully conditional specification statement) 
and PROC MIANALYZE for combining the MI estimates. 
In EPIC-Potsdam, the C-index was computed with the SAS 
code published by Liu et al,35 and the NRI was computed 
using parts of a published SAS macro %nriidi by Lars 
Berglund36 and adaptation to MI.
Results
The baseline characteristics of the EPIC-Potsdam 
and GNHIES98 cohort populations are presented in 
table 1. Participants of EPIC-Potsdam were mainly in the 
age range of 35–65 years and therefore on average older 
than participants from the GNHIES98 cohort with an 
age range of 18–79 years. Participants of EPIC-Potsdam 
also had a lower waist circumference, were more physi-
cally active, more likely to have had a diagnosis of hyper-
tension, more likely to be former rather than current 
smokers and less likely to have a positive family history 
with one affected parent when compared with partic-
ipants from the GNHIES98 cohort. Still, the two study 
populations showed similar GDRS points and 5-year 
diabetes risk.
The results from Cox regression to derive the clinical 
GDRS are shown in table 2. The HR for an increment of 
1 point in the original GDRS score was 1.009 (95% CI 
1.008 to 1.009), and the allocated score points in the clin-
ical GDRS based on the beta-coefficient were accordingly 
0.9 per point of the original GDRS. HbA1c was a strong 
independent risk factor, with an HR of 1.893 (95% CI 
1.754 to 2.044) per unit (% points); allocated points in 
the clinical GDRS score were 63.8 per unit. Score points 
for the clinical GDRS can thus be calculated using the 
following equation:
 
Clinical GDRS points = 0.9 × Original GDRS points
+63.8 × HbA1C (%)  
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Table 1 Baseline characteristics for participants of the 








Sex (% male) 38.7 49.1 
Age (years) 49.6±8.9 42.6±25.4 
Waist circumference (cm) 85.7±12.8 89.0±21.7 
Body height (cm) 168±8.7 170±15.0 
Prevalent hypertension (%) 31.1 18.2 
Former smoker (% <20 units/
day) 
22.9 10.9 
Former smoker (% ≥20 units/
day) 
8.9 9.4 
Current smoker (% <20 units/
day) 
14.8 20.7 
Current smoker (% ≥20 units/
day) 
5.7 14.3 
Wholegrain intake (bread, 
muesli) (50 g portion/day) 
1.0±1.2 1.3±1.5 
Coffee consumption (150 g 
portion/day) 
2.8±2.1 2.7±2.5 
Intake of red meat (150 g 
portion/day) 
0.3±0.2 0.6±0.3 
Physical activity (hours/week) 6.0±5.7 1.1±2.2 
One parent with diabetes (%) 21.5 28.1 
Both parents with diabetes 
(%) 
2.3 2.0 
At least one sibling with 
diabetes (%) 
5.1 5.1 
GDRS points 481±134 492±264 
Five-year diabetes risk (%) 2.2±4.4 3.6±11.4 
Hemoglobin A1c (%) 5.5±2.1 5.4±1.1 
Presentedvalues are combined means ± standard deviation 
(SD) or relative frequencies from multiple imputation with 
m=10imputations.
EPIC, European Prospective Investigation into Cancer and 
Nutrition; GDRS, German Diabetes Risk Score.
Table 2 Parameter estimates, HR and allocated points in 
the clinical GDRS




0.008601 1.009 (1.008 to 1.009) 0.9 
Hemoglobin 
A1c (%) 
0.638232 1.89 (1.75 to 2.04) 63.8 
GDRS, German Diabetes Risk Score.
Table 3  Discrimination and reclassification of the original 
GDRS and the clinical GDRS in the EPIC-Potsdam and 
GNHIES98 cohort
Performance 
measure EPIC-Potsdam GNHIES98 cohort 
C-indexGDRS 
(95% CI) 




0.87 (0.81 to 0.92) 0.91 
(0.88 to 0.94)* 
NRI (95% CI) 0.26 (0.21 to 0.30) – 
NRInon-cases (95% CI) 0.02 (0.01 to 0.02) – 
NRIcases (95% CI) 0.24 (0.19 to 0.28) – 
*In GNHIES98 cohort, ROC-AUC was calculated based on logistic 
regression.
EPIC, European Prospective Investigation into Cancer and 
Nutrition; GDRS, German Diabetes Risk Score; NRI, net 
reclassification improvement; ROC-AUC, area under the receiver-
operating characteristic curve.
Epidemiology/Health Services Research
The baseline survival function from Cox regression was 
0.99035, and the mean score point observed in the EPIC-
Potsdam study population was 784.13834152. Using this 
information, the calculation of absolute 5-year risk for 




= 1 − 0.99035exp((Clinical GDRS points−784.13834152)/100) 
We next evaluated the prognostic performance of 
the clinical GDRS based on the absolute 5-year risks in 
EPIC-Potsdam. The C-index (95% CI) for the clinical 
GDRS was 0.87 (0.81 to 0.92), larger than the C-index 
for the original GDRS (0.83, 0.81 t 0.84). Overall NRI 
was 0.26 (0.21 to 0.30) with a stronger improvement 
for the cases compared with the non-cases (NRIcases: 
0.24 (0.19 to 0.28); NRInon-cases: 0.02 (0.01 to 0.02)). The 
C-index in the GNHIES98 cohort was generally higher, 
with 0.87 (0.84 to 0.90) for the original GDRS and 0.91 
(0.88 to 0.94) for the clinical GDRS, respectively; however 
the increase in discrimination was of similar magnitude 
(table 3). According to cut-offs of 2%, 5% and 10% 
absolute 5-year risk (or 838, 932 and 1004 clinical GDRS 
points, respectively), sensitivity was 0.88, 0.63 and 0.41, 
while specificity was 0.73, 0.90 and 0.97 in EPIC-Potsdam 
(table 4). The negative predictive value (NPV) was 1, 0.99 
and 0.99, while the positive predictive value (PPV) was 
0.07, 0.14 and 0.23 for the aforementioned risk cut-offs. 
In the GNHIES98 cohort, sensitivity was generally higher 
while specificity was generally lower for the respective 
cut-offs. NPV was similar to EPIC-Potsdam, whereas PPV 
was slightly lower for the three predefined cut-offs of the 
5-year diabetes risk (table 4).
The mean predicted risk was in agreement with the 
observed 5-year incidence in EPIC-Potsdam (2.5% vs 
2.3%), indicating excellent overall calibration. More 
specifically, the calibration plot (figure 1A) showed almost 
perfect agreement between observed and predicted risks 
for the four predefined risk groups in the EPIC-Potsdam 
study, with a slight tendency toward overestimation in the 
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Table 4 Se, Sp, PPV, and NPV for selected cut-offs of predicted risk in the EPIC-Potsdam and GNHIES98 cohort





points (~) Se Sp PPV NPV Se Sp PPV NPV 
0.02 838 0.88 0.73 0.07 1.00 0.97 0.67 0.06 1.00 
0.05 932 0.63 0.90 0.14 0.99 0.81 0.84 0.11 1.00 
0.10 1004 0.41 0.97 0.23 0.99 0.62 0.93 0.17 0.99 
EPIC, European Prospective Investigation into Cancer and Nutrition; GDRS, German Diabetes Risk Score; NPV, negative predictive value; 
PPV, positive predictive value; Se, sensitivity; Sp, specificity.
Epidemiology/Health Services Research
two lower risk groups also reflected by an E:O ratio of 
1.07 (0.99 to 1.16).
Before recalibration, calibration-in-the-large for the 
validation cohort showed generally an overestimation 
when comparing the mean predicted risk of 3.5% with 
the observed 5-year incidence of 2.3%. This was also 
reflected by the calibration plot and an E:O ratio of 1.51 
(1.22 to 1.87) (online supplementary figure 1). When 
restricted to the age range of EPIC-Potsdam, the E:O ratio 
in the GNHIES98 cohort was 1.34 (1.06 to 1.69) (data not 
shown). After recalibration, the mean predicted risk was 
2.4%, and the E:O ratio of 1.02 (0.83 to 1.26) indicated 
perfect agreement between observed and predicted risk. 
The calibration plot showed perfect calibration for the 
two lower risk groups, whereas underestimation was 
evident particularly in the highest risk group (figure 1B).
dIsCussIOn
In this study, we extended the original non-invasive 
version of the GDRS by HbA1c to establish a clinical 
version of the GDRS. In EPIC-Potsdam, that is, the deri-
vation cohort, inclusion of HbA1c in the original GDRS 
improved the accuracy of diabetes risk prediction. The 
clinical GDRS yielded excellent discrimination and 
showed good calibration. In the external validation 
cohort, a nationwide sample from the German adult 
population, the clinical GDRS again showed excellent 
discrimination and convincing calibration.
Main findings
Inclusion of HbA1c into the non-invasive version of the 
GDRS10 22 improved prediction of incident diagnosed 
diabetes in EPIC-Potsdam. An improved prediction for 
the clinical GDRS as compared with the non-invasive 
GDRS was also found in the GNHIES98 cohort. Our 
findings are in accordance with previous studies where 
risk scores based on solely non-invasively measured risk 
factors were extended by HbA1c.37–39 These extended 
risk scores reached a discrimination ranging from a 
C-Index of 0.76 for a risk score including age, sex, body 
mass index, waist circumference and HbA1c to 0.83 
for a risk score including age, sex, diabetes of parents, 
hypertension, waist circumference, smoking, alcohol 
consumption, physical activity, and HbA1c.37 As opposed 
to the clinical GDRS, none of these previous risk scores 
have been externally validated, although strongly recom-
mended before their application in clinical practice.40 41
With regard to calibration, the clinical GDRS showed 
perfect calibration in all predefined risk groups in EPIC-
Potsdam. Only in the two lower risk groups diabetes risk 
was slightly overestimated; however, generally calibra-
tion was excellent as indicated with the E:O ratio of 1.07 
(0.99 to 1.16). In contrast, without recalibration the clin-
ical GDRS overestimated diabetes risk for all risk groups 
in the GNHIES98 cohort with an increasing tendency for 
increasing diabetes risk. This general overestimation was 
further reflected by an E:O ratio of 1.51 (1.22 to 1.87). An 
overestimation of diabetes risk particularly in the highest 
risk group was also observed in previous validation studies 
of the original GDRS.10 12 33 42 43 For example, in a regional 
German cohort study including adults aged 45–83 years, 
the E:O ratio in the highest group of predicted diabetes 
risk was 3.32, whereas it was 1.65 in the lowest group.43 
Also in the EPIC-InterAct study, the E:O ratio of the orig-
inal GDRS before recalibration indicated an overestima-
tion of diabetes risk after 5 years of follow-up (E:O ratio: 
1.78 (1.41 to 2.16)). For a less satisfying model perfor-
mance in the validation study as compared with the orig-
inal study, recalibration of the model is one suggested 
approach.34 41 Following this suggestion, recalibration of 
the original GDRS strongly improved its calibration (E:O 
ratio: 1.01 (0.98 to 1.03)) in a previous validation study.33 
This could also be observed for other diabetes risk scores 
such as Finnish Diabetes Risk Score(FINDRISK) or Fram-
ingham33 and is in accordance with our findings for the 
GNHIES98 cohort.
Implications
Diabetes risk scores may be applied in the clinical context 
to assess individual diabetes risk and thereby identify 
individuals with a high risk for future diabetes.44 Since 
blood parameters such as HbA1c have been shown to 
improve predictive performance of risk scores13 and are 
generally available in the clinical setting in Germany, the 
application of the clinical GDRS in the clinical context 
seems reasonable.
However, compared with the application of other clin-
ical risk scores, the main advantage of our approach 
of extending the original GDRS by HbA1c is that the 
original GDRS can be still applied in a first step. This 
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Figure 1 Calibration plots for the clinical GDRS in the EPIC-
Potsdam study (A) and the GNHIES98 cohort (B). Predicted 
risks were determined using score points, mean score points 
and the baseline survival as derived from EPIC-Potsdam. 
Predicted risks were plotted against observed risks in four 
predefined risk groups (low risk: <2%, still low risk: 2 to <5%, 
increased risk: 5 to <10%, high or very high risk ≥10% 5-year 
risk). Expected-to-observed (E/O) ratios were calculated as 
expected number of cases (as mean predicted risk multiplied 
with the overall sample size) divided by observed number of 
cases; 95% confidence intervals were determined assuming 
a Poisson variance. For calibration in the GNHIES98 cohort, 
the clinical GDRS was recalibrated to account for differences 
in diabetes incidence between the GNHIES98 cohort and 
EPIC-Potsdam.
Epidemiology/Health Services Research
is of particular importance as it has been shown that a 
preceding non-invasive risk assessment increases the 
acceptance of following blood tests.7 As a consequence, 
our approach broadens the field of application of the 
GDRS to use a more precise model in the clinical setting 
by still retaining the original GDRS. This is important, 
since the original GDRS includes modifiable risk factors 
which have great potential for prevention targets by the 
practitioner. Furthermore, including HbA1c in the GDRS 
might increase its acceptance among physicians and thus 
increase its application in the clinical setting in Germany. 
Still, the original GDRS is maintained and can be applied 
to assess individual diabetes risk among the general 
population or in clinical settings without requiring any 
further blood testing.
Limitations
Certain limitations need to be taken into account when 
interpreting the results of this study. In EPIC-Potsdam, 
HbA1c was measured in a case-cohort study nested within 
the EPIC-Potsdam cohort, and therefore a high propor-
tion of missing values occurred for a full cohort analysis 
(Table S1). However, with MI we applied the most accurate 
available approach for dealing with missing values from a 
case-cohort design especially when calculating absolute 
risks and providing a scoring algorithm.14 Furthermore, 
measurements of HbA1c were generally too high for a 
healthy population. Therefore, we corrected these values 
by using representative German survey data. In addition, 
we did not calculate new coefficients for the non-inva-
sively measurable risk factors of the clinical version of 
the GDRS but used the original coefficients to derive the 
score points. Nevertheless, model performance was almost 
identical between the two approaches and we preferred 
the presented algorithm for easier application in clinical 
practice by retaining the original GDRS as an established 
tool for diabetes risk prediction. Finally, we observed 
differences in the age distributions of the derivation and 
validation cohorts; however, to correct for study differ-
ences we applied recalibration. Moreover, a previous vali-
dation study of the original GDRS in GNHIES98 showed 
only a slight difference in discrimination when restricting 
the validation cohort to the age range of EPIC-Potsdam.12 
Overall, for Germany validity was confirmed by evaluating 
model performance in German-wide cohort data and 
through recalibration of the clinical GDRS for application.
As opposed to EPIC-Potsdam, validation through the 
treating physician of self-reported diabetes diagnosis was 
not feasible in the GNHIES98 cohort. Besides, information 
on history of diabetes in siblings was not available. There-
fore, the prevalence of a history of diabetes in siblings 
from EPIC-Potsdam had to be applied as constant. Due to 
the resulting lack of variance in this GDRS component, 
the performance of the clinical GDRS might have been 
underestimated in the GNHIES98 cohort.10 In addition, 
there were differences in the assessment of some GDRS 
components such as dietary intake and physical activity 
between the derivation and validation cohorts. Finally, 
the follow-up rate was only moderate in the GNHIES98 
cohort; however, we applied a weighting factor to account 
for the incomplete follow-up.
COnCLusIOn
Extension of an already precise and valid diabetes risk 
score, which was originally based on only non-invasively 
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measured risk factors, by HbA1c further improved 
its predictive performance. Its validity was externally 
confirmed by nationwide data and recalibration was 
applied to obtain a nationwide well-calibrated model. 
With the clinical GDRS we broaden the field of applica-
tion of the GDRS by providing the opportunity to apply 
the original GDRS as a first step in risk assessment, which 
can then be extended in clinical practice with HbA1c 
whenever it was measured. Hereby physicians may get an 
impression on the patient’s actual lifestyle and formulate 
potential recommendations; with additionally assessing 
HbA1c, the patient’s risk profile can then be evaluated 
from a more detailed perspective.
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